The PQM program helps combat the proliferation of poor quality medicines in countries around the world.
The Promoting the Quality of Medicines (PQM) program is a cooperative agreement between the U.S. Agency for International Development (USAID) and the U.S. Pharmacopeial Convention (USP). Since 1992, USP has worked with USAID to support low- and middle-income countries in addressing critical issues related to medicines information and quality. The PQM program provides technical assistance to build capacity of medicines regulatory authorities and quality assurance systems in countries with weak health systems, and supports the manufacture of quality-assured priority essential medicines for malaria, HIV/AIDS, tuberculosis, neglected tropical diseases, and maternal and child health.
The PQM program was established in response to the growing development and health challenges posed by the proliferation of substandard and falsified medicines in countries around the world. There is increasing recognition of the burden of poor-quality medicines hindering the successful implementation of health strategies, programs, and interventions, especially in low- and middle-income countries. Substandard and falsified medicines can cause treatment failure and adverse reactions, can increase morbidity and mortality, and may contribute to antimicrobial resistance. These medicines represent not only a waste of scarce resources but also a substantial risk to public health. Further, they risk undermining decades of health investments, including those made by USAID.
PQM provides technical assistance to low- and middle-income countries to:
- Strengthen national medicines regulatory, quality assurance, and quality control systems
- Assist local manufacturers to increase the availability of quality-assured priority essential medicines
- Increase capacity to detect falsified, substandard, and unapproved medical products
- Increase collaboration and commitments to advance medicines quality